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Abstract
Background: c-kit is expressed in various cell types during development and it has been linked to
the promotion of cellular migration, proliferation and/or survival of melanoblasts, hematopoietic
progenitors and primordial germ cells. Several reports have proposed a role for the c-kit gene on
carcinogenesis. Gain-of-function mutations are associated with diseases such as mastocytosis and
gastrointestinal stromal tumors among others. However, very little is known about pathologies
associated with loss-of-function mutations. Regarding breast cancer, c-kit protein and mRNA are
highly expressed in normal breast but their expression decreases or is absent in the presence of
breast cancer. We studied the role of c-kit in mammary carcinogenesis in the Ws/Ws rats carrying
spontaneous lack-of-function mutation in the c-kit gene. Fifty day-old virgin female Ws/Ws rats and
their wild type counterparts were injected with either 50 mg/kg body weight of the chemical
carcinogen N-nitrosomethylurea or with vehicle. The animals were followed-up for 6 months.
Fisher 344 rats were used as positive controls for tumor development.
Results: Eleven weeks after treatment, palpable tumors were detected in the Ws/Ws rats. The
tumor incidence was 80% in Ws/Ws rats, while no tumors were observed in the wild type rats (p
= 0.006). Our data show that the lack of c-kit is permissive for the development of mammary tumor
in Ws/Ws rats treated with carcinogen.
Conclusion: We conclude that the lack of c-kit may contribute to an imbalanced homeostatic
state in the mammary gland either by affecting signaling between stroma and epithelium, or through
the lack of mast cells.
Background
Several reports have proposed a role for the c-kit gene on
carcinogenesis. The c-kit gene encodes a protein that is a
member of the tyrosine kinase receptor family. One
known ligand for this receptor is the stem cell factor (SCF)
[1]. c-kit is expressed in various cell types during develop-
ment, namely, endothelial, epithelial and endocrine cells
and it has been linked to the promotion of cellular migra-
tion, proliferation and/or survival of melanoblasts,
hematopoietic progenitors and primordial germ cells [2].
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Spontaneous c-kit mutations have been described in mice
[3], rats [4] and humans [5]. In rodents, c-kit is encoded
by the W locus where several mutant alleles have been
reported. Rats carrying deletions in both alleles of the c-kit
gene at the W locus are called Ws/Ws (for white spotting);
they have black eyes and white coats [4]. In addition to the
depletion of skin melanocytes, the Ws/Ws rats show mac-
rocytic anemia and depletion of mast cells and interstitial
cells of Cajal [6]. Contrary to the W mutant mice, no germ
cell depletion has been observed in these rats allowing
them to be fertile [7].
Both activating and inactivating mutations of c-kit have
been described. Gain-of-function mutations are associ-
ated with mastocytosis and gastrointestinal stromal
tumors among other diseases [6,8,9]. However, very little
is known about pathologies associated with loss-of-func-
tion mutations. Kitamura et al. [6] observed spontaneous
forestomach papillomas and antral ulcers in W/Wv mice
carrying c-kit  loss-of-function mutation. These lesions
were attributed to spontaneous bile reflux due to the
depletion of interstitial cells of Cajal that regulate the
rhythmical contraction of the gastrointestinal tract, rein-
forcing the notion that pathologic lesions may arise as a
consequence of a disruption in the normal cell interac-
tions of the stomach wall.
Mast cells are believed to play a role in the maintenance
of epithelial and connective tissue integrity. Under physi-
ological conditions, mast cells can generate and release
numerous potent mediators (i.e. heparin, proteases,
cytokines, etc), thus directly or indirectly affecting tissue
growth, differentiation and survival. Some of these func-
tions appear to occur via the interaction between the tyro-
sine kinase c-kit receptor present in the mast cells and its
ligand SCF produced by cells such as endothelial cells,
fibroblasts, melanocytes, etc. [10].
Mast cells may also be important players during tissue
remodeling. For instance, bone density and microstruc-
ture of mast cell deficient mice are comparable to those of
their wild type counterpart. However, mast cell deficient
mice showed marked delay in onset and decreased dura-
tion of remodeling, as well as diminished synthesis of new
bone matrix [10]. During the physiological remodeling of
the mammary gland that occurs during pregnancy and lac-
tation, an increased number of mast cells were observed at
the time when the mammary stroma is replaced by lob-
ulo-alveolar structures; however, the number of mast cells
declines dramatically during lactation when the gland is
occupied exclusively by lactiferous units [11].
As mentioned above, Ws/Ws rats are depleted of mast cells
as a consequence of lacking c-kit. In order to further clarify
any association between mast cells, lack of c-kit expression
and cancer, we studied mammary tumorigenesis in the
context of c-kit null environment in the Ws/Ws rats and
their wild-type counterparts using a classical model of
chemical carcinogenesis induced by N-nitrosomethylurea
(NMU).
Results
Ws/Ws and wild type mammary gland morphology
Whole mounts of abdominal/inguinal mammary glands
obtained from approximately 8 month-old animals (rats
were euthanized at the end of the experiment, 6 months
after carcinogen or vehicle exposure) showed that both
Ws/Ws and wild type glands have a dense ductal tree with
multiple side-branching and alveolar buds (Figure 1A).
Histologically, the mammary glands from both Ws/Ws
and wild type rats were indistinguishable; also, both
expressed estrogen receptor alpha and had a continuous
layer of myoepithelial cells surrounding the luminal epi-
thelial cells (Figure 1B). The only histological difference
observed was the lack of mast cells in the Ws/Ws rats (Fig-
ure 1B).
Tumor latency and incidence
None of the wild type rats treated with NMU developed
palpable tumors throughout the duration of the experi-
ment. In NMU-treated Ws/Ws rats the first tumor was pal-
pated 11 weeks after the carcinogen injection. Tumors in
the positive control F344 rats were palpable starting 10
weeks after treatment (Table 1).
The total incidence of tumors, including palpable and
microscopic ones, in Ws/Ws rats was 80%. There was no
statistically significant difference with the positive control
F344 rats (p = 0.343). Tumors were palpable in 4 of the 5
Ws/Ws rats and up to three tumors per rat were recorded.
In addition to the palpable tumors, the mammary gland
whole mounts of the Ws/Ws rats showed numerous
microscopic lesions (Figure 2A). These lesions were
removed, paraffin embedded and analyzed; the his-
topathological evaluation confirmed their neoplastic
nature (Figure 2B Ws/Ws).
The whole mounts from the NMU-treated wild type mam-
mary glands also showed microscopic lesions (Figure 2A).
However, upon histopathological examination those
lesions were classified as not neoplastic (Figure 2B wild
type). These results are statistically different from the Ws/
Ws (p = 0.006) and F344 (p = 0.002) tumor incidence.
None of the vehicle-treated animals, either Ws/Ws or wild
type, showed neoplastic lesions during the duration of the
experiment. Necropsy was performed in all NMU-treated
animals at the end of the experimental observation; no
macroscopic tumors were observed in organs other than
the mammary glands.Cancer Cell International 2008, 8:5 http://www.cancerci.com/content/8/1/5
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Mammary gland histopathology
Tumors and microscopic lesions were classified following
the criteria described by Russo et al [12]. The tumors
observed in Ws/Ws rats were described as adenocarci-
noma and carcinoma of cribriform type, ductal carcinoma
and fibroadenoma. Figure 2B (Ws/Ws) are representative
sections of these tumors. One of the carcinomas had both
lobular and ductal components. The mammary glands of
the rat that did not develop neoplasia presented dilated
and hyperplastic ducts. Tumors developed in the F344
positive control animals were classified as carcinomas of
papillary or cribriform type, the most commonly
observed tumor types in NMU-treated rats [12].
The mammary glands of NMU-treated wild type rats
showed no signs of neoplasia. However, three mammary
glands of these nulliparous rats had ductal secretion (Fig-
ure 2B, wild type), one also showed dilated and hyper-
plastic alveolar structures with abundant secretion
resembling milk (Figure 2B wild type). The dilated ducts
were similar in both Ws/Ws and wild type mammary
glands. None of the wild-type rats developed preneoplas-
tic lesions such as intraductal hyperplasias and did not
show differences in mast cell numbers compared to vehi-
cle controls (data not shown).
c-kit expression
Immunostaining for c-kit (CD117) was performed in nor-
mal mammary glands from Ws/Ws and wild-type rats.
Normal mammary glands and mammary tumors from
F344 rats were solely used as controls for the quality of
NMU preparation and immunostaining. Luminal epithe-
lial cells from F344 rats showed the highest cytoplasmic
and membrane c-kit expression, followed by those in the
wild type rats (Figure 3A and 3B). As expected, the Ws/Ws
mammary glands did not stain for c-kit (Figure 3D). In
addition, the mammary tumors from F344 control rats
revealed a complete lack of c-kit expression (Figure 3C)
which is in agreement with reports describing the loss of
c-kit in breast cancer [13].
Table 1: Tumor incidence in Ws/Ws and wild type rats. Fisher 
344 rats were used as a positive control.
Rat # Tumors 
removed
Latency 
(weeks)
Microscopic 
neoplastic lesions
Ws/Ws
1 YES 19 YES
2 YES 19 YES
3N O- N O
4 YES 12 YES
5 YES 11 YES
Wild type
1N O- N O
2N O- N O
3N O- N O
4N O- N O
5N O- N O
6N O- N O
F344
1 YES 10 YES
2N O- Y E S
3N O1 0 Y E S
4 YES 10 YES
Characterization of Ws/Ws and wild type adult rat mammary  glands Figure 1
Characterization of Ws/Ws and wild type adult rat mammary 
glands. Panel A: Mammary whole mounts of normal wild type 
and Ws/Ws rats. Both glands show a dense ductal network 
with multiple branching points. Panel B: Histological sections 
of the glands depicted in Panel A. As expected, the only mor-
phological difference is the absence of mast cell in the Ws/
Ws animals. LN: lymph nodes. Ws/Ws: c-kit null rats. Immu-
nohistochemistry: positive cells stained brown; Harris's 
hematoxylin was used as counterstaining. Scale bars: Panel A: 
3.2 cm; Panel B: 50 μm.Cancer Cell International 2008, 8:5 http://www.cancerci.com/content/8/1/5
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Discussion
Our data show that the lack of c-kit is permissive for the
development of mammary tumor in Ws/Ws rats treated
with the carcinogen NMU. Moreover, wild-type rats, in
which c-kit is present, did not show signs of neoplasia.
Although the number of animals used in this experiment
seems small, the observed differences are statistically sig-
nificant, biologically relevant and plausible. In this
regard, NMU is known to induce neoplasia in susceptible
strains at the dose used (as it is demonstrated by the
tumors developed in our positive control F344 rats) and
not to induce mammary tumors in resistant strains (i.e.
Copenhagen, Wistar-Kyoto). Hence, this is a reliable
model chosen precisely for the high tumor incidence
observed in the susceptible strains and absence of effect in
the resistant ones, thus allowing comparisons using a
small number of animals per group.
The rationale for using Ws/Ws rats instead of the W/Wv c-
kit  null mice to study mammary gland carcinogenesis
derives from the fact that c-kit mutant mice lack functional
ovaries [3], and thus are unlikely to develop an estrogen-
dependent tumor. Moreover, the rat model is considered
overall to be the most suitable animal model due to the
many similarities to the human disease regarding hor-
mone-dependence and histopathology [14,15].
A link between c-kit gain of function mutations and neo-
plasms such as mast cell tumors, gastrointestinal stromal
tumors, seminoma/dysgerminoma and small cell lung
carcinoma has been reported [6,8,16,17]. However, to our
knowledge, other than the spontaneous gastric papillo-
mas, no stringent correlations between c-kit loss of func-
tion mutations and spontaneous tumors have been
found. Herein, we observed for the first time that c-kit null
rats develop mammary carcinomas after treatment with
NMU, a chemical commonly used in mammary carcino-
genesis studies.
Among the possible explanations for tumor development
in c-kit  null rats, there are two that deserve particular
attention: 1) the lack of a "protective" effect due to the
absence of the c-kit tyrosine kinase receptor which may
contribute to a disruption in the cell-cell communication
Immunostaining for c-kit Figure 3
Immunostaining for c-kit. Panels A and B: c-kit is expressed in 
the cytoplasm of luminal epithelial cells (arrows) and mast 
cells (arrowhead) present in the stroma of control F344 and 
wild type rat mammary glands. Panel C: c-kit is not expressed 
in a mammary tumor obtained from a control F344 rat. Panel 
D: as expected, Ws/Ws rats do not express c-kit. Counter-
staining: Harris' hematoxylin. Ws/Ws: c-kit null rats. Scale 
bar: 50 μm
Carcinogen-treated Ws/Ws rats developed mammary carci- nomas Figure 2
Carcinogen-treated Ws/Ws rats developed mammary carci-
nomas. Panel A: whole mounts of mammary glands obtained 
from NMU-treated wild type and Ws/Ws rats. Only the 
mutant rats developed tumors while the microscopic lesions 
observed in the wild type mammary glands were benign 
lesions. Panel B: Histological sections of the region of interest 
outlined (yellow lines) in the whole mounts. The wild type 
rats showed large dilated ducts containing secretion (aster-
isks) whereas the Ws/Ws developed frank carcinomas. Sec-
tions were stained with hematoxylin and eosin. LN: lymph 
nodes. Ws/Ws: c-kit null rats. Scale bars: Panel A: 3.2 cm; 
Panel B: 100 μm and 50 μm.Cancer Cell International 2008, 8:5 http://www.cancerci.com/content/8/1/5
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between c-kit expressing mammary epithelial cells and
SCF-expressing fibroblasts, or mast cells and fibroblasts,
and 2). the lack of a "protective" effect due to the absence
of mast cells. Because these rats are outbred, we cannot yet
rule out the effect of mast cells in carcinogenesis given that
a mast cell or bone marrow transplantation from wild
type to c-kit null rats is unfeasible. A way to overcome this
shortcoming would be to test this hypothesis in a three-
dimension tissue culture setting where mast cells, epithe-
lial cells and fibroblasts are co-cultured.
It is plausible that the lack of c-kit receptor may have addi-
tional covert phenotypic effects in addition to the already
described anomalies, including the absence of mast cells.
c-kit is expressed on the membrane and/or cytoplasm of
ductal and alveolar epithelial cells in normal breast [18].
Protein and mRNA expression of c-kit is high in normal
breast, significantly lower in carcinomas in situ and almost
completely undetectable in invasive breast cancer [13].
Benign breast lesions also showed a decreased expression
of c-kit but of lower magnitude than that observed in
malignant lesions [19-21]. Thus, it has been suggested
that the process of malignant progression correlates with
the progressive loss of c-kit and that this may reflect the
role played by the c-kit/SCF pathway in the maintenance
of normal growth of mammary epithelium [13,20]. In
this regard, Samoszuk and Corwin showed that when
imatinib mesylate (Gleevec) was used to inhibit tyrosine
kinase activity, including c-kit, there was an acceleration
in the growth rate of mammary adenocarcinomas in mice
while the number of mast cells was similar in both treated
and untreated animals [22]. A similar association between
decrease expression of c-kit and tumor incidence was
observed in the thyroid. While low levels of c-kit are
expressed in normal thyroid glands and in 60% of benign
lesions, the receptor remained undetectable in 60–90% of
the follicular and papillary carcinomas [23].
Mast cells, together with other innate immune cells, have
been associated with cancer development by mechanisms
that include induction of DNA damage by free radicals,
paracrine regulation of intracellular pathways, promotion
of angiogenesis and tissue remodeling, etc. [24]. However,
mast cells have also been described as the "Jekyll and
Hyde" of tumor growth, suggesting that they may have
different roles in different environments [25]. Regarding
patients with breast cancer, several publications have
associated mast cells with both poor and good prognosis.
Kashiwase et al. suggested that mast cells may play a dele-
terious role in breast cancer because a significantly greater
number of them were found in malignant lesions com-
pared to benign lesions [26]. In contrast, Aaltomaa et al.
[27] reported that a high number of mast cells in the
tumor stroma significantly correlated with a favorable
prognosis. More recently, mast cells in the peritumoral
stroma of human breast cancer were correlated with good
prognosis [28].
Tanooka et al. showed that after subcutaneous injection of
methylcholanthrene, the primary subcutaneous tumor
incidence was significantly higher in mast cell-deficient
mice than in their wild type counterparts; additionally,
after bone marrow transplantation to replenish mast cells,
the tumor incidence decreased to that observed in the
wild type mice [29], concluding that the higher tumor
incidence in the mutant mice was due to the lack of mast
cells. The authors also observed that the growth rate of
these tumors was similar in both types of mice, suggesting
that the putative protective effect of mast cells would
become null after the tumors grew to a certain size [29].
Our results using the c-kit null rats are in general agree-
ment with this report. The main difference between these
two experiments is that none of the wild type rats in our
study developed neoplasias.
A close relationship between mast cells and their sur-
rounding stroma has been reported. For instance, heparin
from mast cells affects the conversion of soluble collagen
to collagen fibers in vitro [30]. Also, mast cells are in close
contact or attached to fibroblasts and they enhance
fibroblast-mediated contraction of collagen via direct cell-
cell contact due in part by the c-kit/SCF interactions [31].
Depletion of mast cells also reduced proteases and pro-
tease-activators involved in tissue remodeling [32].
Finally, the role played by epithelial c-kit receptor and its
SCF ligand produced by fibroblasts in stroma-epithelium
communication in the mammary gland remains
unknown.
Altogether, our data suggest that 1) the absence of c-kit
receptor in the epithelial cells and 2) the lack of mast cells
would affect the homeostatic stroma-epithelial relation-
ships. Therefore, proper stroma remodeling and epithe-
lium maintenance would not occur, thus contributing to
the high tumor incidence observed in c-kit null rats. One
might speculate that the mammary tumor susceptibility
observed in these rats may be due to altered tissue interac-
tions that are only manifested when the animals are chal-
lenged with the carcinogen NMU [33,34]. Under similar
conditions, the wild type rats seem to be able to overcome
the carcinogenic effect of NMU. To our knowledge, both
Brown Norway and Donryu rats develop tumors [35].
Thus we hypothesize that the "tumor resistance" observed
in these wild type rats may be due to the presence of an
intact interaction between the different components of
the mammary gland. These important yet to be uncovered
mechanisms are the object of our current research.Cancer Cell International 2008, 8:5 http://www.cancerci.com/content/8/1/5
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Conclusion
In summary, mast cell depletion is a consequence of lack
of c-kit. This receptor has a broad physiological function
mediated in part by the interaction with its ligand SCF.
The lack of c-kit may contribute to an imbalanced home-
ostatic state in organs that undergo extensive remodeling
either directly, by affecting signaling between stroma and
epithelium, and/or indirectly, by the lack of mast cells.
Methods
Animals
The wild type rats are of the Brown Norway and Donryu
genetic background, from which mutant Ws/Ws rats were
obtained. The generation of Ws/Ws rats was described
elsewhere [4]. Wild type and Ws/Ws rats are outbred and
they were purchased from Japan SLC, Inc (Hamamatsu,
Shiziuoka Prefecture, Japan). Fisher 344 (F344) rats were
purchased from Harlan (Indianapolis, IN). The animals
had access to food and water ad libitum and were main-
tained on a 14:10 hours light:dark cycle. Care and proce-
dures were in accordance with the Guidelines for the Care
and Use of Animals and the Tufts-New England Medical
Center Institutional Animal Care and Use Committee.
Carcinogen treatment
A single dose of 50 mg/kg body weight of the direct acting
carcinogen NMU (Sigma, St. Louis, MO) was injected
intraperitoneally to virgin 52 day-old female Ws/Ws (n =
6) and wild-type rats (n = 6). A similar number of animals
were injected with vehicle (0.85 g/l sodium chloride, pH
5) as negative controls. To our knowledge, there is no data
indicating how Ws/Ws or their wild type counterpart will
respond upon exposure to the carcinogen NMU. There-
fore, tumor-susceptible F344 rats were injected with the
same dose of NMU and served as positive control for the
effect of NMU on mammary carcinogenesis.
Starting 1 month after treatment, the animals were pal-
pated weekly and the tumor latency period was recorded.
Tumors were removed when they reached 1 cm in diame-
ter. If they reached this size before the termination of the
experiment (6 months after carcinogen injection) the
tumor was removed and those animals were kept alive
until the end of the experiment. The animals were sacri-
ficed and thoracic and abdominal/inguinal mammary
glands were removed. One Ws/Ws animal died shortly
after the NMU injection, probably as a result of toxicity by
the carcinogen. No necropsy could be performed. Conse-
quently, the final number of Ws/Ws rats was 5.
Tissue processing and stainings
Abdominal/inguinal mammary glands were whole-
mounted, fixed in phosphate-buffered formalin and
stained with carmine alum as described before [34]. In
addition, thoracic mammary glands and tumors were
fixed in phosphate-buffered formalin and paraffin
embedded. Five microns thickness tissue sections were
stained with hematoxylin and eosin or toluidine blue (pH
2) to evaluate the presence of mast cells. The samples were
blindly analyzed by a pathologist.
Immunohistochemistry for c-kit
An antigen retrieval method using microwave pretreat-
ment and 0.01 M sodium citrate buffer (pH 6) was per-
formed as previously described [36]. A polyclonal rabbit
antibody for c-kit (CD 117, Dako, Carpinteria, CA) was
used at 1:150 dilution. The antigen-antibody reaction was
visualized using the streptavidin-peroxidase complex,
with diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) as the chromogen. Counterstaining was per-
formed with Harris' hematoxylin and the sections were
analyzed using an Axioskop 2 Plus microscope (Carl
Zeiss, Munchen-Hallbergmoos, Germany) and an Axio-
Cam HR color digital camera (Carl Zeiss).
Statistics
Chi-square analysis was performed to compare tumor
incidence between positive control F344 rats and Ws/Ws
or wild type rats. The same test was used to compare inci-
dence between Ws/Ws and wild type animals.
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